S080_BrCaRes_Schneeweiss et al.

ABSTRACT: In patients with primary breast cancer, neoadjuvant chemotherapy with doxorubicin plus pemetrexed followed by docetaxel (AP-D) is associated with a pathologic complete response (pCR) rate of 16.5%, and doxorubicin plus cyclophosphamide followed by docetaxel (AC-D) is associated with a pCR rate of 20.2%. Our primary objective was to identify single predictive genetic markers for achievement of pCR following either AP-D or AC-D treatment. Our main secondary objective was to detect treatment-group specific, pCR-predictive gene signatures.

ORGANISM(S): Homo sapiens

DISEASE(S): breast adenocarcinoma

SUBMITTER: Daniel Haag 

PROVIDER: E-TABM-1186 | biostudies-arrayexpress |

REPOSITORIES: biostudies-arrayexpress